TIGIT: A potential immunotherapy target for gynecological cancers

被引：4

作者：

Jiang, Siyue ^{[1
]}

Wang, Wenhua ^{[2
]}

Yang, Yongxiu ^{[3
]}

机构：

[1] Third Peoples Hosp Suining, Suining, Sichuan, Peoples R China

[2] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China

[3] Lanzhou Univ, Hosp 1, Dept Obstet & Gynecol, Key Lab Gynecol Oncol Gansu Prov, Lanzhou, Gansu, Peoples R China

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2024年 / 255卷

关键词：

Gynecological cancer; Immunotherapy; Immune checkpoint; TIGIT; ACTIVATING RECEPTOR CD226; T-CELL IMMUNOGLOBULIN; OVARIAN; CHECKPOINT; ANTITUMOR; BLOCKADE; REVEALS; CD155; PD-1; PVR;

D O I：

10.1016/j.prp.2024.155202

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Gynecological cancer represents a significant global health challenge, and conventional treatment modalities have demonstrated limited efficacy. However, recent investigations into immune checkpoint pathways have unveiled promising opportunities for enhancing the prognosis of patients with cancer. Among these pathways, TIGIT has surfaced as a compelling candidate owing to its capacity to augment the immune function of NK and T cells through blockade, thereby yielding improved anti-tumor effects and prolonged patient survival. Global clinical trials exploring TIGIT blockade therapy have yielded promising preliminary findings. Nevertheless, further research is imperative to comprehensively grasp the potential of TIGIT-based immunotherapy in optimizing therapeutic outcomes for gynecological cancers. This review primarily delineates the regulatory network and immunosuppressive mechanism of TIGIT, expounds upon its expression and therapeutic potential in three major gynecological cancers, and synthesizes the clinical trials of TIGIT-based cancer immunotherapy. Such insights aim to furnish novel perspectives and serve as reference points for subsequent research and clinical application targeting TIGIT in gynecological cancers.

引用

页数：11

共 88 条

[21] Recurrent or primary metastatic cervical cancer: current and future treatments [J].

Gennigens, C. ;

Jerusalem, G. ;

Lapaille, L. ;

De Cuypere, M. ;

Streel, S. ;

Kridelka, F. ;

Ray-Coquard, I .

ESMO OPEN, 2022, 7 (05)

[22] Coming of Age: CD96 Emerges as Modulator of Immune Responses [J].

Georgiev, Hristo ;

Ravens, Inga ;

Papadogianni, Georgia ;

Bernhardt, Guenter .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[23] Integrated genomic characterization of endometrial carcinoma [J].

Getz, Gad ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Lander, Eric ;

Sivachenko, Andrey ;

Sougnez, Carrie ;

Lawrence, Mike ;

Kandoth, Cyriac ;

Dooling, David ;

Fulton, Robert ;

Fulton, Lucinda ;

Kalicki-Veizer, Joelle ;

McLellan, Michael D. ;

O'Laughlin, Michelle ;

Schmidt, Heather ;

Wilson, Richard K. ;

Ye, Kai ;

Ding, Li ;

Mardis, Elaine R. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Lee, Darlene ;

Li, Haiyan I. ;

Marra, Marco A. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Plettner, Patrick ;

Schein, Jacqueline E. ;

Sipahimalani, Payal ;

Tam, Angela ;

Varhol, Richard J. ;

Robertson, A. Gordon ;

Pashtan, Itai ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Schumacher, Steven E. ;

Tabak, Barbara .

NATURE, 2013, 497 (7447) :67-73

[24] Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack [J].

Gur, Chamutal ;

Ibrahim, Yara ;

Isaacson, Batya ;

Yamin, Rachel ;

Abed, Jawad ;

Gamliel, Moriya ;

Enk, Jonatan ;

Bar-On, Yotam ;

Stanietsky-Kaynan, Noah ;

Coppenhagen-Glazer, Shunit ;

Shussman, Noam ;

Almogy, Gideon ;

Cuapio, Angelica ;

Hofer, Erhard ;

Mevorach, Dror ;

Tabib, Adi ;

Ortenberg, Rona ;

Markel, Gal ;

Miklic, Karmela ;

Jonjic, Stipan ;

Brennan, Caitlin A. ;

Garrett, Wendy S. ;

Bachrach, Gilad ;

Mandelboim, Ofer .

IMMUNITY, 2015, 42 (02) :344-355

[25] CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer [J].

He, Weiling ;

Zhang, Hui ;

Han, Fei ;

Chen, Xinlin ;

Lin, Run ;

Wang, Wei ;

Qiu, Haibo ;

Zhuang, Zhenhong ;

Liao, Qi ;

Zhang, Weijing ;

Cai, Qinbo ;

Cui, Yongmei ;

Jiang, Wenting ;

Wang, Han ;

Ke, Zunfu .

CANCER RESEARCH, 2017, 77 (22) :6375-6388

[26] Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression [J].

Howitt, Brooke E. ;

Strickland, Kyle C. ;

Sholl, Lynette M. ;

Rodig, Scott ;

Ritterhouse, Lauren L. ;

Chowdhury, Dipanjan ;

D'Andrea, Alan D. ;

Matulonis, Ursula A. ;

Konstantinopoulos, Panagiotis A. .

ONCOIMMUNOLOGY, 2017, 6 (02)

[27] The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer [J].

Jamieson, Amy ;

Bosse, Tjalling ;

McAlpine, Jessica N. .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

[28] Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice [J].

Jayasingam, Sharmilla Devi ;

Citartan, Marimuthu ;

Thang, Thean Hock ;

Zin, Anani Aila Mat ;

Ang, Kai Cheen ;

Ch'ng, Ewe Seng .

FRONTIERS IN ONCOLOGY, 2020, 9

[29] PD-1 and TIGIT coexpressing CD8+CD103+tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy [J].

Jiang, Fang ;

Mao, Mingyi ;

Jiang, Shiyang ;

Jiao, Yuhao ;

Cao, Dongyan ;

Xiang, Yang .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127

[30] The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function [J].

Johnston, Robert J. ;

Comps-Agrar, Laetitia ;

Hackney, Jason ;

Yu, Xin ;

Huseni, Mahrukh ;

Yang, Yagai ;

Park, Summer ;

Javina, Vincent ;

Chiu, Henry ;

Irving, Bryan ;

Eaton, Dan L. ;

Grogan, Jane L. .

CANCER CELL, 2014, 26 (06) :923-937

← 1 2 3 4 5 6 7 8 9 →